Twist Bioscience

. @SynBioBeta 2026 attendees, we have a sneak peek for you! @EmilyLeproust is telling the story behind it all: what happens when DNA is no longer the bottleneck: synbiobeta.com/read/emily-lep… @johncumbers

Customer spotlight! Jasmine Zhou and team “developed a DNA methylation-based liquid biopsy assay for detecting multiple diseases, including several types of cancer, from cell-free DNA (cfDNA) isolated from blood samples at low cost.” genomeweb.com/cancer/ucla-te…

@SynBioBeta 2026 attendees, we have a sneak peek for you! @EmilyLeproust is telling the story behind it all: what happens when DNA is no longer the bottleneck: synbiobeta.com/read/emily-lep… @johncumbers

Rare ribosome tweak in E. coli reveals possible antibiotic target - Phys.org apple.news/A3spsgXN2Sduze…

@johncumbers @EmilyLeproust We are super excited for @SynBioBeta next week! See you soon 🧬

“If we can remove the technical barriers to engineering biology, we enable innovation across multiple industries at once.” I love this framing from @EmilyLeproust , CEO and co-founder of @TwistBioscience Bioscience, because it captures why DNA synthesis is so foundational to the future of synthetic biology. Emily Leproust will be speaking at @SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… Emily’s SynBioBeta talk, “From DNA to Data, Powering the AI Age of Biology,” will trace how Twist moved from DNA synthesis to becoming part of the infrastructure for AI-driven discovery. Twist began with a powerful idea: high-quality synthetic DNA, available at scale, can unlock what researchers are able to engineer. A decade later, that idea has become a platform spanning gene synthesis, NGS, target enrichment, antibody discovery, and pooled gene synthesis. Twist has helped make synthetic DNA more accessible, more scalable, and more central to how modern biology gets built. Now the field is entering a new phase. AI can explore sequence space at extraordinary speed. But design alone is not enough. The real bottleneck becomes whether we can build, test, and learn fast enough to keep up. That is where the next decade gets exciting. This is exactly the kind of conversation that makes SynBioBeta special. You can read about these shifts online. But the relationships, partnerships, and breakthrough conversations happen in person. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. I’m excited to have Emily joining us in San Jose to share how DNA synthesis is helping power the AI age of biology. Visit the SynBioBeta website to read the full article: synbiobeta.com/read/emily-lep…

@SynBioBeta @EmilyLeproust See you sooooon! 🧬

“With AI transforming how sequence space is explored, the opportunity to connect synthesis directly to discovery has never been greater.” That is the future @EmilyLeproust , CEO and co-founder of @TwistBioscience, will be speaking about at #SynBioBeta 2026. Emily Leproust will be speaking at #SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: syntheticbiologysummit.com/?utm_source=Li… When Twist was founded in 2013, DNA synthesis was still slow, expensive, and inaccessible for many researchers. Over the past decade, Twist has helped change that with a silicon-based platform built to deliver high-quality synthetic DNA at scale. That platform has since expanded far beyond gene synthesis into NGS, target enrichment, antibody discovery, and pooled gene synthesis at scales that once would have seemed impossible. The throughline is clear: make DNA easier to build, and researchers can design, test, and iterate faster across biology, medicine, agriculture, materials, diagnostics, and more. As Emily put it, “If we can remove the technical barriers to engineering biology, we enable innovation across multiple industries at once.” That matters even more now as AI begins to explore sequence space faster than traditional wet lab workflows can validate. This is why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. At SynBioBeta, the people building the next era of DNA synthesis, AI-designed biology, and scalable bioengineering will be together in one place. Visit the #SynBioBeta website to read the full article: synbiobeta.com/read/emily-lep…

Amazon Bio Discovery just launched & highlighted recent work with @MSKcancercenter. Now you can read the paper: amazon.science/publications/a… ~300K novel antibody molecules were designed. 100K top candidates were tested by Twist, cutting time from a traditional year to just weeks

AACR 2026: What a week. Watching the scientists, clinicians, and innovators who are literally rewriting the future of cancer care, THAT was the moment we'll carry with us long after the conference ended. #AACR26 @TwistBioscience

From spacecraft ranging to massive DNA data storage: Composite ranging codes as indices and error correction references Thank you to the authors for choosing Twist oligo pools to support this work. science.org/doi/10.1126/sc…

First place 🥇

Second place 🥈

🧬 Tomorrow is DNA Day! 🧬 To celebrate our favorite holiday of the year, we're putting your knowledge to the test! Take our DNA Quiz and see if you can outsmart your colleagues, all while competing for exciting prizes!

April news wrap-up! Read about all of our April highlights including our partnership with the newly launched Amazon Bio Discovery, our 13th anniversary, and more! Also see where we will be in May. linkedin.com/pulse/base-pai…

Coming Soon! Complex Gene Synthesis. 🧬 A major update to our Gene Synthesis platform is on its way to help you make difficult gene sequences in predictable timescales. Be the first to know when Complex Gene synthesis will become simple with Twist: twistbioscience.com/products/genes…

UCLA researchers develop low-cost blood test to detect multiple cancers and other diseases from a single sample | UCLA newsroom.ucla.edu/releases/ucla-…

We're proud to support our partner Invenra for their presentation at #PEGSBoston! 🧬 🗓️ Monday, May 11 | 12:10 PM Our strategic licensing agreement is bringing Invenra's B-Body bispecific platform to more researchers than ever: investors.twistbioscience.com/news-releases/…

Top 3 winners (announced April, 29th) will receive one of the following: Bose speaker YETI water bottle Cotopaxi hip pack Take the quiz today and celebrate DNA Day with @TwistBioscience: surveymonkey.com/r/B3RJ8J6